Your browser doesn't support javascript.
loading
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Vergote, I; du Bois, A; Floquet, A; Rau, J; Kim, J-W; Del Campo, J M; Friedlander, M; Pignata, S; Fujiwara, K; Colombo, N; Mirza, M R; Monk, B J; Tsibulak, I; Calvert, P M; Herzog, T J; Hanker, L C; Meunier, J; Lee, J-Y; Bologna, A; Carrasco-Alfonso, M J; Harter, P.
Affiliation
  • Vergote I; Department of Gynaecological Oncology, BGOG & University Hospitals Leuven, Leuven, Belgium. Electronic address: Ignace.vergote@uzleuven.be.
  • du Bois A; Department of Gynecology and Gynecologic Oncology, AGO & Kliniken Essen Mitte-Evang, Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
  • Floquet A; GINECO & Institut Bergonié, Bordeaux, France.
  • Rau J; Coordinating Center for Clinical Trials, AGO & Philipps-University of Marburg, Marburg, Germany.
  • Kim JW; Department of Obstetrics and Gynecology, KGOG & Seoul National University, Seoul, Republic of Korea.
  • Del Campo JM; GEICO & Vall d'Hebron University Hospital, Barcelona, Spain.
  • Friedlander M; ANZGOG & Department of Medical Oncology, Prince of Wales Clinical School, UNSW, Randwick, NSW, Australia.
  • Pignata S; MITO and Department of Uro-gynaecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G Pascale", IRCCS, Naples, Italy.
  • Fujiwara K; Department of Gynecologic Oncology, JGOG & Saitama Medical University International Medical Center, Saitama, Japan.
  • Colombo N; MaNGO & IEO, European Institute of Oncology, IRCCS, Milan and University of Milano-Bicocca, Milan, Italy.
  • Mirza MR; Department of Oncology, NSGO & Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Monk BJ; Division of Gynecologic Oncology, Californian Consortium & University of Arizona and Creighton University, Phoenix, AZ, USA.
  • Tsibulak I; Department of Gynecology and Obstetrics, AGO Austria & Medical University Innsbruck, Innsbruck, Austria.
  • Calvert PM; Cancer Trials Ireland, Innovation House, Glasnevin, Dublin, Ireland.
  • Herzog TJ; NYGOG & University of Cincinnati (UC) College of Medicine, UC Cancer Institute, Cincinnati, OH, USA.
  • Hanker LC; Department of Gynecology & Obstetrics, AGO & University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Department of Gynecology and Obstetrics, Goethe-University Frankfurt, Frankfurt, Germany.
  • Meunier J; Hôpital de La Source, service d'oncologie médicale, Centre Hospitalier Régional d'Orléans, Orléans, France.
  • Lee JY; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Bologna A; MaNGO & Azienda Unità Sanitaria Locale di Reggio Emilia IRCCS, UO di Oncologia Medica, Reggio Emilia, Italy.
  • Carrasco-Alfonso MJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Harter P; Department of Gynecology and Gynecologic Oncology, AGO & Kliniken Essen Mitte-Evang, Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Gynecol Oncol ; 155(2): 186-191, 2019 11.
Article in En | MEDLINE | ID: mdl-31519320
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Pyrimidines / Sulfonamides / Angiogenesis Inhibitors / Carcinoma, Ovarian Epithelial Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Pyrimidines / Sulfonamides / Angiogenesis Inhibitors / Carcinoma, Ovarian Epithelial Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2019 Type: Article